Absci Corporation (ABSI)
NASDAQ: ABSI
· Real-Time Price · USD
2.62
-0.09 (-3.32%)
At close: Jun 27, 2025, 3:59 PM
2.63
0.44%
After-hours: Jun 27, 2025, 05:45 PM EDT
-3.32% (1D)
| Bid | 2.63 |
| Market Cap | 334.01M |
| Revenue (ttm) | 3.64M |
| Net Income (ttm) | -107.48M |
| EPS (ttm) | -0.93 |
| PE Ratio (ttm) | -2.82 |
| Forward PE | -3.94 |
| Analyst | Buy |
| Ask | 2.7 |
| Volume | 3,439,987 |
| Avg. Volume (20D) | 3,098,393 |
| Open | 2.74 |
| Previous Close | 2.71 |
| Day's Range | 2.61 - 2.75 |
| 52-Week Range | 2.01 - 6.33 |
| Beta | 2.07 |
About ABSI
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ABSI
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ABSI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Absci Corporation is scheduled to release its earnings on Aug 13, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-1.69%
ABSI stock has given up its prior gain. Absci shar...
Unlock content with
Pro Subscription
1 month ago
-1.69%
Absci shares are trading higher after the company announced it began dosing the first participants in its Phase 1 ABS-101 clinical trial.
2 months ago · seekingalpha.com
Absci Corporation: A Potential Turnaround Play In Biotech Amid A Tumultuous MarketAbsci Corporation stock has dropped since January, driven by weak earnings and broader biotech sector pressures. Despite weak financials, Absci's internal pipeline, including ABS-101 and ABS-201, offe...
